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From the Editor’s Desk
Pediatrics is the branch of medicine that deals
with the care of infants, children and adolescents.
The age limit is newborn till 21 years. Islamic
writers such as Ibn Sina have contributed to GrecoRoman and Byzantine medicine. The Persian
scholar and doctor Al-Razi published a thesis on
diseases in children. Neonates, infants and children
differ markedly from adults, physiologically.
Developmental delays, genetic mutations and
congenital defects are of greater concern to
pediatricians as compared to physicians practicing
adult medicine.
Moving a step further, pediatric pathologist is more
of a generalist then a specialist. This field covers a
wide spectrum of abnormalities occurring during

development, extending through childhood and
culminating in adolescence.
This is the first time that an issue of LABRAD
has been exclusively dedicated to pathologies of
the pediatric population. We have covered topics
related to inherited bleeding disorders, endocrine
abnormalities, malignant diseases and genetic
disorders to name a few.
This year’s last issue ends on a “thematic” note.
Hope our readers will be enlightened as always. We
will continue to publish thematic issues like these in
the years to come.
Natasha Ali

Overview on Approach to Inherited Bleeding
Disorders
Dr Nadia Nasir
Haematology

Inherited bleeding disorders may be due to a vascular
defect, a platelet disorder or a coagulation defect.
Table 1 shows the causes of inherited bleeding
disorders based on this classification:
Table 1: The Causes of Inherited Bleeding Disorder
Type of Bleeding
Disorder

Common Inherited
Bleeding Disorders

Vascular Defect

1. Hereditary Hemorrhagic Telengiectasia
2. Ehlers Danlos Syndrome
3. Henoch-Schonlein Purpura

Platelet Defect

1. Glanzmann Thrombasthenia
2. Bournard Soulier Syndrome

Coagulation
Defect

1. Haemophillia A (Factor Viii Deficiency)
2. Haemophillia (Factor Ix Deficiency
3. Afibrinogenaemia/Dysfibrinogenaemia

Approaching a child with bleeding disorder mainly
consists of the following:
1. History taking
2. Clinical Examination
3. Laboratory Findings

Inherited bleeding disorders compared to acquired
bleeding disorders, tend to have an early age
of presentation, where bleeding is a dominant
feature and usually with a positive family history.
The pattern of bleeding is relatively predictable
depending on the etiology. Vascular and platelet
disorders tend to be associated with bleeding from
the mucous membrane and into the skin, whereas in
coagulation disorders the bleeding is often into joints
or soft tissue as shown in Table 2.
Table 2: Adapted from Essential Haematology
Platelet/Vessel
Wall Diseases

Coagulation
Diseases

Mucosal Bleeding

Common

Rare

Petechiae

Common

Rare

Deep Haematomas

Rare

Common

Bleeding From Cuts

Persistent

Minimal

Gender

Equal

Mostly Males

An appropriate and reliable laboratory approach,
encompassing first-line (screening) and second3

VOL. 41, ISSUE 3

DECEMBER 2015

line (specific) testing, is essential to screen,
diagnose, and monitor patients who have
bleeding diatheses Figure 1. The available
clinical assays also can be grouped according to
whether they evaluate components of primary
hemostasis or coagulation factors.

Figure 1: adapted from pedsinreview aappublications

Assays for Evaluating Primary Hemostasis
A complete blood count and evaluation of the
peripheral blood smear usually constitute
the required first step. The bleeding time
is the historical screening test for defects
of primary hemostasis, but low sensitivity
and specificity in children limit its utility.
Newer platelet function analyzers (PFAs)
are now available in clinical laboratories but
cannot be relied on to identify all patients
who have von Willibrand disease or platelet
function defects, and their routine use
remains controversial. Therefore, when these
disorders are considered, specific testing
(vWF indices, platelet aggregation studies)

4

should be performed as demonstrated in the above
figure.
Assays for Evaluation of Coagulation Factor
Function
The prothrombin time (PT) and
activated PTT are coagulation
screening tests performed on
citrated plasma. The PT is
reported commonly along with the
International Normalized Ratio
(INR) to adjust for different reagent
sensitivities. The PT is a measure
of the extrinsic (FVII) and common
pathway (FV, FX, prothrombin,
fibrinogen) clotting factors. The
PTT measures the contact system
(prekallikrein, FXII) as well as the
intrinsic (FVIII, FIX, FXI) and
common pathway clotting factors.
Sensitivities of various PT and PTT
reagents vary and may yield normal
values in the presence of mild factor
deficiencies. Therefore, specific
factor assays should be performed
for patients who are strongly
suspected of having a bleeding
disorder. Table 3 shows interpretation of laboratory
results for common inherited bleeding disorder.

Table 3: Adapted from essential haematology
Factor IX
Normal

VWB
Normal

Bleeding Time Normal

Normal

Increased

PT

Normal

Normal

Normal

APTT

Prolonged

Prolonged

Prolonged

Mixing
Studies

Pt Aptt Corrected Pt Aptt Corrected Pt Aptt Corrected
By Normal Plasma By Normal Plasma By Normal Plasma

Complete
Blood Counts

Factor VII
Normal

Factor Assays Vii Deficiency

Ix Deficiency

Vwb Deficiency
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Diagnostic Approach to Haemoglobinopathies
Dr Sidra Asad Ali and Dr Anila Rashid
Haematology

Haemoglobinopathies refer to a diverse group
of inherited disorders characterized by a
reduced synthesis of one or more globin chains
(thalassaemias) or the synthesis of structurally
abnormal haemoglobin. They encompass a
heterogeneous group of disorders associated with
mutations in both the alpha-globin and beta-globin
genes.
Diagnosis of haemoglobinopathies, including
thalassaemias, can result from either a clinical
suspicion of a disorder of globin chain synthesis or
from follow-up of an abnormality detected during
screening. Screening may be carried out as part of
a well-defined screening program or be an ad hoc
or opportunistic test.
Step wise approach to Diagnosis
Complete Blood Count
Structural haemoglobinopathies may have
an impact on the red cell indices, which are
critical to the diagnosis of thalassaemias. The
key components of the CBC include: Hb, red
cell count, mean corpuscular volume (MCV),
and red cell distribution width (RDW). The
thalassaemias generally are classified as
hypochromic and microcytic anemias. Hence the
MCV is a key diagnostic indicator and reported
in femtoliters, in most adult populations ranges
from ~80 to 100 fL. Thalassaemic individuals
have a reduced MCV, and studies suggest that
an MCV of 72 fL is maximally sensitive and
specific for presumptive diagnosis of thalassemia
syndromes. RDW may provide information
useful as an adjunct to diagnosis but is not
useful as alone indicator. The RBC count is
also useful as a diagnostic adjunct because the
thalassemias produce a microcytic anemia with
an associated increase in the RBC number.
Various indices utilizing these CBC components
have been developed with a view to providing a
mathematical derivation to reliably differentiate
iron deficiency from thalassemia minor. None are
useful in all clinical settings, and probably none
exceed the value of the MCV alone in selecting
cases for subsequent investigations.

Hb H Inclusion
Hb H refers to an insoluble Hb tetramer comprising
four β-globin chains. Hb H arises in the setting of
α-thalassemia where the decreased production of
α-globin chains leads to β-globin excess. Oxidation
of these tetramers provokes precipitation, which can
be visualized microscopically. But the Hb H stain
is nonspecific in that other nucleic acid or protein
precipitates also stain.
In the setting of Hb H disease, a disorder in
which three of four α-globin chain genes are not
expressed, 30–100 per cent of red cells contain
typical inclusions. In contrast, α-thalassemia
minor may be associated with as few as one
inclusion-containing cell in 1000–10 000 cells.
The absence of Hb H inclusions therefore does
not exclude thalassemia trait, but the presence of
typical inclusions may be helpful in confirming a
presumptive diagnosis.
Electrophoresis
Traditionally, electrophoresis has been the method
of choice for identification and quantification of
variant Hbs. Commercial, rapid electrophoretic
methods have been developed that allow for
separation at pH 8.4 (alkaline) and pH 6.2 (acid) on
agarose gels.
However, it is slow, labor-intensive, and inaccurate
in the quantification of low-concentration Hb
variants (e.g., Hb A2) or in the detection of fast Hb
variants (Hb H, Hb Barts).
Isoelectric Focusing
IEF is an electrophoretic technique with
excellent resolution. Although labor-intensive
and time-consuming, it has been used to
identify and quantify Hbs. IEF is an equilibrium
process in which Hb migrates in a pH gradient
to a position of zero net charge. The narrow
bands obtained on IEF allow for more precise
and accurate quantification than standard
electrophoresis.
5
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Capillary Isoelectric Focusing
It is a hybrid technique combining the capillary
electrophoresis sensitivity of detection with the
automated sampling and data acquisition of HPLC.
Many published works have described the utility
of CIEF in the detection and quantification of Hb
variants. Separation of the Hb in this method is
related to the isoelectric point of the Hb, and this
may enhance inter-laboratory reproducibility.
High Performance Liquid Chromatography
Cation-exchange HPLC is emerging as the method
of choice for the initial screening of Hb variants
(including neonatal screening where this is
mandated) and for quantification of Hb A2 and Hb
F concentrations. The Bio-Rad Variant (Bio-Rad
Laboratories) is an automated cation-exchange
HPLC instrument that has been used to quantify
Hb A2, Hb F, Hb A, Hb S, and Hb C. College
of American Pathologists studies have shown
equivalence or superiority over electrophoretic
methods. In comparison with haemoglobin
electrophoresis, HPLC has the following advantages:
1. The analysers are automated, therefore require
less staff time and permit processing of large
batches.
2. Very small sample volumes (5 μL) are sufficient
for analysis.
3. Quantification of normal and separated variant
haemoglobins is available on every sample.
4. Provisional identification of a larger proportion
of variant haemoglobins can be made.

5. δ chain variants (recognition of which is
important in the diagnosis of β thalassaemia
heterozygosity) are more easily detected.
DNA Analysis
After presumptive identification of
hemoglobinopathies and thalassemia syndromes,
and particularly for purposes of genetic counseling,
defining the mutation or deletion present may
be required. Typically, deletional mutations
causing α-thalassemia syndromes and some rare
β-thalassemias are diagnosed using Southern blot
hybridization of particular restriction enzyme
digests to labeled complementary gene probes.
PCR techniques using allele-specific probes after
globin gene amplification, allele-specific primers,
or deletion-dependent amplification with flanking
primers are used in definition of known globin chain
mutations/deletions. For unknown mutations, several
PCR-based methods, including denaturing gradient
gel electrophoresis and single-strand conformation
polymorphism analysis, as well as sequencing of the
amplified globin gene DNA may be used.
With increasing global awareness and mass
screening programs undertaken at various levels by
health care system, the responsibility for laboratory
personnel has greatly enhanced in detection and
prevention of haemoglobinopathies. Detection of
asymptomatic carriers by reliable laboratory methods
is the cornerstone of prevention of this serious health
problem. Awareness about the diagnostic problems as
well as their solutions is also very important so that
one does not miss a single case.

Biochemical work up of Nephrotic Syndrome
in Paediatrics Population
Dr Khushbakht Arbab
Chemical Pathology

Childhood nephrotic syndrome can start at any age,
but usually begins between the ages of two and
five years. It is a rare condition that affects about
16 out of every 100,000 children at any given time,
and it affects more boys than girls. It is extremely
unlikely that other children in a family will also
have nephrotic syndrome. While there are a few
types of nephrotic syndrome which do run in
6

families, these are very rare. Nephrotic syndrome, or
nephrosis, is defined by the presence of nephroticrange proteinuria, edema, hyperlipidemia, and
hypoalbuminemia.
Along with obtaining a complete medical history,
a series of biochemical tests are required in order
to arrive at an accurate diagnosis that verifies the
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presence of the illness. In addition, imaging of the
kidneys (for structure and presence of two kidneys)
is sometimes carried out, and/or a biopsy of the
kidneys. Laboratory evaluation of patients suspected
of nephrotic syndrome may include the following:
Urinalysis
Microscopic hematuria is present in 20 per cent of
cases of nephrotic syndrome but cannot be used
to distinguish between minimal change nephrotic
syndrome and other forms of glomerular disease.
Red blood cell casts, if present, are suggestive of
acute glomerulonephritis, such as post infectious
nephritis, or a nephritic presentation of chronic
glomerulonephritis, such as membranoproliferative
glomerulonephritis. Furthermore granular casts may
be present and are non-specific to etiology.
Urine Protein Quantification
In children it is defined as protein excretion of
more than >3.5 g per 1.73 m2 per 24 hours or a
first-morning urine protein/creatinine of 2-3 mg/mg
creatinine or greater.
Serum Albumin
Serum albumin levels in nephrotic syndrome are
generally less than 2.5 g/dL, however values as low
as 0.5 g/dL are not uncommon due to renal albumin loss.

Lipid Panel
Heavy proteinuria leading to hypoalbuminemia
causes compensatory increase in lipoprotein
synthesis. This results in hyper lipoproteinemia.
Elevated total cholesterol, low-density lipoprotein –
cholesterol and triglycerides may be noted.
Serum Electrophoretic
Patterns in nephrotic syndrome show decreased
albumin, and increased alpha 2-macroglobulin
fraction.
Other Tests
Serum creatinine levels are usually normal unless the
disorder has progressed to chronic kidney disease.
Complete blood count, serum electrolytes, and
serum creatinine may also be tested. To evaluate
the etiology of nephrotic syndrome, antibodies to
HIV, hepatitis B and C, complement studies and
antinuclear antibody and anti–double-stranded DNA
antibody (in selected patients) may also be done.
The prognosis for nephrotic syndrome under
treatment is generally good although this depends on
the underlying cause, the age of the patient and their
response to treatment. It is usually good in children,
because minimal change disease responds very well to
steroids and does not cause chronic kidney disease.

Transient Abnormal Myelopoiesis
Dr Hira Qadir
Haematology

Introduction
Transient Abnormal Myelopoiesis (TAM)
is a unique disorder of Down syndrome (DS)
newborns that presents with clinical and
morphologic findings indistinguishable from
acute myeloid leukemia (AML). Hematologic
abnormalities affecting red blood cells, white
blood cells, and platelets are common in DS,
particularly during childhood. Population-based
studies show that risk for leukemia is 10-20
times higher in individuals with DS compared
with the overall population, with a particularly
striking increase of the incidence of acute

myeloid leukemia in young children with DS
(approximately 150-fold).
Incidence
Data regarding the incidence of TAM in DS vary
depending on the screening practices and diagnostic
criteria used. Reported incidence rate among infants
with DS range from 10 - 30 per cent.
Disease Mechanism
TMD arises during fetal development and
hematopoiesis. In the setting of trisomy 21,
7
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megakaryocyte-erythroid progenitors (MEPs)
are expanded during hematopoiesis in the fetal
liver. Development of TAM appears to require the
acquisition of a somatic mutation of the gene coding
for the hematopoietic transcription factor GATA-1.
GATA-1 mutations in TAM result in the expression
of an amino-terminally truncated GATA1 protein
(GATA1s). The functional consequence is impaired
megakaryocytic differentiation and uncontrolled
proliferation of a population of TAM blasts as
shown in Figure 1.

Figure 1: Disease Mechanism of TAM in Down Syndrome

Source: Xu G et al. Frequent mutations in the GATA-1 gene in the transient
myeloproliferative disorder of Down syndrome. Blood 2003; 102:2960.

Clinical Presentation
Most patients are diagnosed within the first weeks
of life. Some first come to clinical attention when
circulating blasts are noted on a peripheral smear
performed for screening purposes. Others are overtly
ill with a wide range of physical and laboratory
abnormalities at the time of diagnosis. Infiltration
of solid organs with TAM is usually restricted to
the liver, spleen, marrow, and skin. Hepatomegaly
(60 per cent) and splenomegaly (42 per cent)
are commonly present at diagnosis of TAM.
Lymphadenopathy is infrequent in TAM (two per
cent of patients). At times, skin lesions consisting of
papules, vesicles, and pustules may be the first sign
pointing to TAM in a newborn with Down syndrome.
On biopsy, these lesions may show infiltration by
immature myeloid cells.
Laboratory Features
Peripheral smear and bone marrow: TAM is
characterized by the frequent presence of blasts
(usually megakaryoblasts) in the peripheral blood
Figure 2. Moderate leukocytosis is common
(median white blood counts (28 to 40 x 109/L).
8

Figure 2: Blasts from the peripheral blood of 1-day-old with trisomy 21.
Source: Pathology of Myeloid Proliferations Related to Down Syndrome. Author:
Cherie H Dunphy, MD; Chief Editor Cherie H Dunphy

Hemoglobin (median 14.6 to 14.8 g/L) and platelet
count (median 96 to 125 x 109/L) are only mildly
decreased. The flow cytometry immunophenotype
of the non-lymphoid, non-erythroid blasts of TAM is
characterized by the expression of megakaryoblastic
/ megakaryocytic (CD61, CD41, CD42), stem cell
(CD34, CD117), myeloid (CD13, CD33), and nonlineage (CD4, CD7, CD56) antigens. Bone marrow
examination demonstrates abnormal megakaryocytic
maturation in 75 per cent and dyserythropoiesis in 25
per cent.
Diagnostic Criteria
Diagnostic criteria for TAM are not universal. In
most cases, the diagnosis is made based on the
identification of blasts in the peripheral blood with a
megakaryoblastic/megakaryocytic immunophenotype
on flow cytometry. The most definitive test to identify
TMD blasts is detection of a somatic mutation of
GATA1, typically in exon two or three.

DECEMBER 2015

Prognosis and Course
TAM resolves spontaneously in the vast majority of
patients. The two adverse outcomes of TAM are early
death during the neonatal period and development
of AML. TAM has an early mortality of up to 20 per
cent and estimated five-year overall survival (OS)
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and event-free survival (EFS) rates of 85 and 63
per cent, respectively. Approximately 20 per cent
(13 to 30 per cent) of the patients with TAM go on
to develop AML within the first four years of life.
Due to this substantial risk for subsequent AML, all
patients with a history of TAM are followed for signs
and symptoms of progression.

Introduction of Maple Syrup Urine Disease
(MSUD) Profile in Biochemical Genetics
Laboratory at AKUH
Dr Noreen Sherazi and Dr Sheharbano Imran
Chemical Pathology

Maple Syrup Urine Disease (MSUD) is an inherited
amino acids metabolic disorder caused by a
deficiency of the branched-chain alpha-keto acid
dehydrogenase complex leading to a buildup of the
branched chain amino acids (leucine, isoleucine,
valine and alloisoleucine) and their toxic by-products
(ketoacids) in the blood and urine. Clinically it can
be classified as classic MSUD or other variants of
MSUD.
Clinical Indications for MSUD Testing
l
l
l
l

l
l
l
l

Maple syrup odor in urine, the first clinical sign of
MSUD, detectable 12 hours after birth.
Poor feeding by age two to three days.
Deepening encephalopathy including lethargy.
Intermittent apnea, opisthotonus, and stereotyped
movements (such as fencing and cycling) by age
four to five days.
Coma and central respiratory failure that may
occur by age seven to ten days.
Poor growth.
Irritability or developmental delays, later in
infancy or childhood.
Ketonuria and encephalopathy if stressed by
fasting, dehydration, or infectious illness.

Biochemical Characteristics of MSUD
Elevated plasma concentrations of branchedchain amino acids (BCAAs) (leucine, isoleucine,

and valine) and allo-isoleucine, accompanied
by a more generalized disturbance of plasma
amino acid concentration ratios, detectable
by 12-24 hours of age in affected infants on a
normal protein intake. Occasionally, plasma
concentrations of isoleucine or valine may be low
or normal, but plasma concentration of leucine is
invariably elevated. Elevated plasma concentration
of allo-isoleucine is specific and diagnostic for
MSUD.
MSUD Profile at AKUH Clinical Laboratory
We have recently introduced MSUD profile at out
biochemical genetics laboratory section of clinical
chemistry. This profile includes:
l Leucine
l Isoleucine
l Valine
l Allo-isoleucine
As compared to our full plasma amino acid
quantification, this shortened program allows
the separation and quantification of the four
branched chain amino acids. In addition to this,
alloisoleucine is also identified in this profile
unlike full plasma amino acid quantification. It is
used as a specific and sensitive diagnostic marker.
Quantitative amino acid analysis of these four
branched-chain amino acids is crucial for the
diagnosis and monitoring of MSUD.

9
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Urinary Tract Infections (UTI) in Children
Dr Fizza Farooqui
Microbiology

Urinary tract infections are a common cause of
unexplained fever in infants and young children.
Most guidelines suggest that fever of >38°C in this
age group should raise suspicion of UTI, and thus,
it is of utmost importance that they have their urine
tested within 24 hours.
Definitions
Guidelines proposed by National Institute of Health
and Clinical Excellence (NICE) recommend that
children be divided into three age groups; <3 months,
three months to <3 years, and ≥3 years for the
purpose of diagnosis. Children <3 months should
have urgent microscopy of urine (>5 white blood
cells/high power field) as well as cultures also from
other sites (blood, cerebrospinal fluid if indicated) as
they are at high risk of serious illness. For children
three months to <3 years, urgent urine microscopy
and culture is recommended, dipstick testing
needs further discussion between microbiologists,
pediatricians and primary care doctors. Dipstick
testing is recommended for children >3 years, where
a positive nitrite and leukocyte esterase denote
infection. The American Academy of Pediatrics
(AAP) recommends that diagnostic strategies depend
on whether the clinician decides to start antimicrobial
therapy or not. Diagnosis is dependent on the
presence of pyuria and growth of ≥50,000 colony
forming units of a single urinary pathogen from a
urine specimen collected with a sterile technique.
Samples
Collection of urine samples remains highly
challenging in the younger age group. Clean
catch urine specimens are recommended by NICE
guidelines, samples collected in urine collection

bags and pads have been reported to show equal
rates of contamination. If none of these are possible,
in/out catheters or ultrasound guided supra-pubic
aspiration are the recommended methods of choice
for collection. AAP recommends in/out catheters or
supra pubic aspirates as the only methods of choice
for urine collection.
Antibiotic Treatment
Increase in antibiotic resistance, inconvenience, lack
of compliance, and increased cost all add weight
to the decision of discontinuation of antibiotic
prophylaxis by the NICE guidelines. The AAP
recommends that antibiotic treatment should start
based on route of administration, local antibiogram,
and subsequently upon susceptibility results from
culture reports. The recommended duration of
antibiotic therapy is 7-14 days.
Preventive Measures
NICE guidelines advise that regular bladder
emptying, general hygiene measures, drinking
adequate amounts of fluids, breastfeeding and
circumcision may prevent recurrence of UTI.
AAP guidelines suggest that ultrasonography
of the kidneys and bladder should be performed
to detect structural abnormalities, and a voiding
cystourethrogram obtained if there is evidence of
hydronephrosis, scarring, or other complex clinical
circumstances are encountered.
Thus, a high index of suspicion, appropriate
sample collection and testing followed by regular
follow up to prevent recurrent UTI remain
the mainstay for management of urinary tract
infections in children.

Key points:
Microscopy

Dipstick analysis (D/R)

Urine Culture (Clean catch/ suprapubic/ in/out catheters)

<3 months

√

-

√ (in addition to blood culture)

3 months - <3 years

√

Debatable

√

>3 years

√

√

√

Age Group

10
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Labrad Quiz
Dr Lena Jafri
Chemical Pathology

A 6 year old girl was brought to a pediatrician for not
being able to walk properly since one and a half year.
Mother (Para +8) explained that her marriage was
consanguineous and two of their boys (12 years and
10 years old) had deformed bones and were unable to
walk.. On examination, there are skeletal deformities
of both upper and lower limbs, frontal bossing and
pallor. Her extremities have widened wrists and ankles.
The laboratory and radiological evaluation included:
Serum Creatinine
Serum Calcium
Serum Phosphorus
Alkaline phosphatase
25-hydroxy Vitamin D
Parathyroid hormone

0.5 mg/dl (0.5-1)
8.7 mg/dl (8.6-10.2)
1.8 mg/dl (2.5-4.5)
1917 U/l (45-129)
32 ng/ml (>30)
90 pg/ml (16-87)

The pediatrician wanted to confirm his suspicion and
ordered TMP-GFR in this patient.
Questions:
1. Which disease is the pediatrician suspecting?

4. What is the pathophysiology of this disease?

2. Why did the pediatrician order TMP-GFR?

5. Which other Vitamin D metabolite testing would
be helpful in establishing the diagnosis in this 		
patient?

3. How is TMP-GFR calculated?

An Overview of Congenital Adrenal Hyperplasia
Dr Sibtain Ahmad
Chemical Pathology

Introduction
Congenital adrenal hyperplasia (CAH), an autosomal
recessive inherited defects of enzymes involved in
adrenal steroidogenesis due to mutations in specific
genes. The common functional defect in each
disorder is impaired cortisol secretion, resulting in
hyper secretion of corticotrophin-releasing hormone
(CRH) and adrenocorticotropic hormone (ACTH)

and consequent hyperplasia of the adrenal glands.
Those affected may present clinically as a classic
(more severe) or nonclassic (less severe) type.
About 75% of those with a classic deficiency will
have a “salt-wasting” form that includes decreased
aldosterone and leads to an excess loss of fluids, low
sodium, and high potassium that, when severe, can
be life-threatening. More than 90% of cases of CAH
are caused by a defect in the enzyme 21-hydroxylase
11
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(21OHD), which is caused by a mutation in the
CYP21A2 gene. Four other enzyme deficiencies in
the steroid biosynthesis pathway, along with one
cholesterol transport protein defect, account for the
remaining cases Figure 1.

irregular menstruation , excess muscle growth or
early development of pubic and armpit hair.
List of Tests available for Diagnosis of CAH at
AKUH Laboratory
Diagnosis and differential diagnosis
of CAH always requires the
measurement of several steroids.
Patients with CAH due to steroid
21-hydroxylase defects/ deficiency
usually have very high levels of
androstenedione. Additionally
17-OHP levels are usually even
higher, while cortisol levels are low
or undetectable Table 1. All three
analytes should be tested when CAH
is suspected.
Patients with CAH due to steroid
11 β-hydroxylase enzyme defects/
deficiency present with low
levels of cortisol, aldosterone
and renin. Whereas the levels of
11-deoxycorticosterone (11-DOC)
are elevated because deficiency of
11 β-hydroxylase deficiency causes
decreases conversion of 11-DOC to

Figure 1: Pathways of Steroid Biosynthesis in the Adrenal

Signs and Symptoms of CAH
Signs and symptoms associated with
CAH depend upon the type of enzyme
deficiency and vary over time, less
severe in non-classic diseases, getting
worse in illness or stress to a lifethreatening adrenal crisis in classic
type.

Table 1: Biochemical Features in Different Forms of CAH
Cortisol

ACTH

Blood Pressure

Androgen

Estrogen

21 β-OH

↓

↑

↓

↑ Adrenal

-

11 β-OH

↓

↑

↑

↑ Adrenal

-

17 α-OH

↓

↑

↑

↓ Adrenal &
Testicular

↓

Deficiency

Salt-wasting CAH signs and symptoms may
include: Abnormal heart rhythm, rapid heart rate,
confusion, dehydration, hyperkalemia, irritability,
hypoglycemia, hypotension, hyponatraemia and
vomiting. Females with classic 21OHD deficiency
may have ambiguous external genitalia (external
sex organs that are not clearly male or female
with normal reproductive organs uterus, fallopian
tubes, and ovaries) due to the diversion of pathway
towards excess androgen production called as
hyperandrogenism. Hyperandrogenism signs or
symptoms in both males and females may include:
accelerated skeletal growth (tall during childhood
but short as adults), acne, deep voice, enlarged
external genitalia, hirsutism in females, infertility,
12

corticosterone and aldosterone.
The 17 α-OH enzyme deficiency is a rare variant
of CAH and is characterized by hypertension
in most cases. It presents with elevated levels
of pregnenolone, progesterone, 11-DOC and
corticosterone. However renin, aldosterone and
cortisol levels are deficient.
The battery of tests performed of CAH diagnosis or
monitoring are:
1.		 Serum 17-hydroxyporgesterone (17OHP):
a.		 Screening: A 17-OHP test may be ordered
			 as a screening test of choice for newborn 		
			 screening to detect CAH due to
			 21-hydroxylase deficiency. The test may be
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			 repeated if the screening result is elevated in
			 order to confirm the initial results. Table 2
			 shows the normal ranges of 17-OHP.

steroidogenic acute regulatory protein or 17 alphahydroxylase deficiencies are characterized by low
DHEA-S levels.

Table 2: Normal ranges of 17Hydroxy Progesterone in Children
of different age Groups

4.		 Serum Testosterone: Approximately 10%
of androstenedione is metabolized in the body to
testosterone, a potent androgen. Consequently
pronounced elevations are found in CAH.

b.		
			
			
			

Stage

Range (ng/mL)

Cord blood

9.0 - 50.0

Premature

0.26 - 5.68

Newborn-3days

0.07 - 0.77

Pre-pubertal child

0.03 - 0.90

Diagnosis: Measurement of 17-OHP in the
blood may be used to aid in the diagnosis of
CAH in older children and adults who may
have a milder, “late-onset” form.

c.		 Monitoring: If someone is diagnosed with
			 CAH, a 17-OHP test may be used periodically
			 to monitor the effectiveness of treatment.
2.		 ACTH stimulation test:
Administration of 250 ug of cosyntropin (a synthetic
ACTH) provides a pharmacologic stimulus to the
adrenal glands, maximizing hormone secretion.
The different forms of CAH due to 21OHD may
be determined based on baseline and stimulated
values of 17-OHP, the immediate precursor to the
21-hydroxylase enzyme Table 2.
Table 2: Interpretation of Results of 17OHP; 60 minutes after
ACTH Stimulation
Levels

Interpretation

<9.9 ng/mL

Likely unaffected

10- 100 ng/mL Non-Classical congenital Adrenal Hyperplasia
>100 ng/mL

Classic Congenital Adrenal Hyperplasia

3. Dehydroepiandrosterone Sulfate (DHEA-S):
CAH due to 3 beta-hydroxysteroid deficiency is
associated with excessive DHEA-S production.
Lesser elevations may be observed in 21-OHD
deficiency and 11 β-OH deficiency. By contrast,

5.		 Plasma Renin: Elevated plasma renin activity
values, particularly the ratio of renin to aldosterone,
are markers of impaired mineralocorticoid synthesis.
6.		 Serum Electrolytes: especially sodium and
potassium are routinely done in monitoring of CAH
patients.
7.		 Plasma Glucose: is tested to evaluate for
hypoglycemia.
8.		 Additional tests: Karyotyping and pelvic and
abdominal ultrasonography are further utilized
diagnostic modalities. Kidney function and liver
function tests may also be tested during management
of these patients.
Burden of CAH in Pakistan
The true incidence of CAH in Pakistan remains
unidentified due to the absence of new born
screening program, lack of diagnostic testing
facilities & disease awareness in the society and
failure of case identification by primary physicians.
A study from our center revealed that of the 152
children registered for 17-hydroxyporegeterone
(17-OHP) testing, sixty-three (41.4 per cent) were
diagnosed with CAH. Among these salt wasting,
simple virilization and non-classical CAH was found
in 40 (63 per cent), 18(29.0 per cent) and 5 (8.0
per cent) patients respectively. Another study from
Pakistan showed variable frequency of referrals from
different provinces of Pakistan. Higher frequency
of cases with suspected CAH was observed from
Sindh (23.7 per cent) as compared to other provinces.
These studies show that CAH is not an uncommon
disease, thus a well-structured and appropriate
screening program of CAH is the need of time.

13
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Role of Histopathology in the Diagnosis of
Paediatric Renal Tumours
Dr Nasir-Ud-Din and Dr Arsalan Ahmed
Histopathology

Introduction
Paediatric renal tumours represent a relatively
common group of childhood solid neoplasms. The
diagnosis, management and prognosis of paediatric
renal tumours have significantly improved over the
last 40 years. Pathologists have played a significant
role in these developments through their work in
multicentre national and international trials and
studies, by recognizing new tumour entities, as
well as favourable and unfavourable histological
features of different tumours. This review highlights
salient clinical and pathologic features of common
paediatric renal tumours.
Nephroblastoma (Wilms tumor)
Nephroblastomas comprise more than 80 per cent
of renal tumours of childhood. Most often, they are
found in children two to five years old, and they are
relatively uncommon in the first six months of life
and in children older than six years. Most patients
come to medical attention because of a palpable
abdominal mass. Other presentations may include
abdominal pain, hematu¬ria, and hypertension.
Most (90 per cent) cases are sporadic; remainders are
associated with one of the several syndromes, some
of which are associated with abnormalities of the
WT1 gene. Most are unilateral and unicentric, but
bilateral tumours are present in five to 10 per cent
cases, especially in familial cases. Those patients
typically have a younger age at presen¬tation and are
more prone to renal failure.
Nephroblastoma is derived from the nephrogenic
blastemal cells and recapitulates various stages of
the developing kidneys. Histologically, typically
composed of variable mixtures of blastema,
epithelium, and stroma (triphasic), although in some
tumors only two (biphasic) or occasionally only one
(monophasic) component is present. Most tumors
have some degree of epithelial differentia¬tion
manifested either as homologous (resembling normal
nephrogenesis) or heterologous (mucinous and
squamous) cell types. A variety of stromal patterns
may be observed including immature myxoid and
14

spindled mesenchymal cells, smooth muscle, skeletal
muscle, and neuroglial tissue.
For therapeutic and prognostic purposes,
nephroblastomas are histologically divided into two
major categories; those that are highly responsive
to current therapeutic modalities are designated
as nephroblastomas with favorable histology, and
those that do not respond well to chemotherapy are
relegated to the unfavorable histology group. The
latter make up about five per cent of nephroblastomas
and are defined by nuclear anaplasia. Anaplasia
is rare in patients younger than two years but
increases in incidence thereafter. Recognition of
anaplasia requires the presence of markedly enlarged
nuclei that are at least three-fold of non-anaplastic
nuclei and hyperchromasia and atypical multipolar
polyploid mitotic figures. Anaplasia may be diffuse
or focal. It should be emphasized that anaplasia
per se is not an indicator of the aggressiveness of a
nephroblastoma but rather predictive of its resistance
to adjuvant therapy.

Figure: Nephroblastoma.

Triphasic nephroblastoma contains blastemal,
epithelial, and stromal elements
Cystic Nephroma and Cystic Partially
Differentiated Nephroblastoma
Cystic nephromas and cystic partially differentiated
nephroblastomas (CPDNs) are tumours that are
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currently believed to be a part of the spectrum of
nephroblastoma. They present as solitary, wellcircumscribed lesions, consisting of numerous cysts
of different sizes and shapes with no solid areas
apart from the septa. The cysts are lined by flattened,
cuboidal or hobnail epithelium, whereas the septa are
composed of loose or dense fibrous tissue containing
only mature elements (in cystic nephroma) or
blastemal or other poorly differentiated cell types (in
CPDN). Cystic nephromas/CPDNs are treated only
by complete surgical resection, which is why it is so
critical to distinguish them from other renal tumours
that may have a prominent cystic appearance, such
as clear cell sarcoma of kidney, rhabdoid tumor of
kidney or nephroblastoma with cysts (particularly
after preoperative chemotherapy), and which are all
treated with postoperative chemotherapy.

of childhood, especially on needle core biopsies
specimens. Diagnosis is based on morphological
criteria, since there is at present no diagnostic
immunohistochemical or molecular test.
Immunohistochemistry is primarily useful to exclude
other renal tumours,
The classical pattern demonstrates nests ⁄cords of
ovoid, epithelioid or spindled cells with bland nuclei
separated by fibrovascular septa, which demonstrates
a marked ‘chicken wire’ pattern of small blood
vessels. About 90 per cent of tumours show at least
some areas with the classical pattern, but other
appearances are also reported, including myxoid (50
per cent), sclerosing (35 per cent), cellular (26 per
cent), epithelioid (13 per cent), pallisading (11 per
cent), spindle-cell (seven per cent), storiform (four
per cent), and anaplastic (three per cent) patterns.
The prognosis for CCSK has improved significantly
since the introduction of doxorubicin to its treatment.
The only significant histological factor associated
with poor prognosis is the presence of necrosis. A
favourable survival rate is associated with a lower
tumour stage, an age of two to four years at diagnosis
and treatment with doxorubicin. The overall survival
is 69 per cent but this varies from 98 per cent for
stage I to 50 per cent for stage 4 disease.

Figure: Cystic partially differentiated nephroblastoma.

The multilocular cysts are lined with flattened,
cuboidal, or hobnail epithelium.
Clear Cell Sarcoma of the Kidney
Clear cell sarcoma of the kidney (CCSK) is a rare
malignant mesenchymal tumour representing three
per cent of renal tumours of childhood. Its peak
incidence is between two and three years of age,
with a striking male predominance. Presentation is
similar to other renal tumours, and around five per
cent have metastatic disease at presentation, most
commonly involving lymph nodes. Bone metastases
are the most common mode of relapse, followed
closely by lung metastases. Interestingly, in about 20
per cent of cases relapses occur after >3 years, unlike
in nephroblastoma, where >90 per cent of relapses
occur within two years after the diagnosis.
Owing to its numerous patterns, CCSK remains
the most frequently misdiagnosed renal tumour

Figure: Clear Cell Sarcoma,

sheets and nests of tumor cells with pale vesicular
nuclei are separated by thin vascular septa. Tumor
cells are separated from each other by pale to clear
extracel¬lular space that imparts a clear appearance.
Rhabdoid Tumour of Kidney
Rhabdoid tumour of kidney (RTK) is a distinctive,
highly malignant paediatric renal tumour, usually
metastasizes widely and causes the death of the
15
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patient within 12 months of diagnosis. The tumour
has a predilection for infants, with a median age of
11 months; over 80 per cent of patients are under two
years of age, and it virtually never occurs over five
years of age.
Hema¬turia is the most common presentation, and
hypercalcemia is a frequent finding. Reportedly, 15
per cent of infants with rhabdoid tumor of the kidney
have an associated PNET of the posterior fossa
midline. Until recently, the definitive diagnosis could
sometimes be difficult, but with the recent improved
understanding of the genetic basis of the disease and
the availability of specific immunohistochemical
markers, the diagnosis can now be made with
certainty, even on a needle biopsy specimen.
Characteristic histological features are the presence
of large, non-cohesive tumour cells with eccentric
large nuclei and very prominent eosinophilic central
nucleoli, and focally hyaline intracytoplasmatic
inclusions. Immunohistochemically, vimetin
demonstrates characteristic strong dot-like
perinuclear positivity in a significant proportion of
cells and INI1 immunopositivity is characteristically
absent in the nucleus of cells of rhabdoid tumour.
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present with a palpable abdominal mass, although
an increasing number of tumours are detected
sonographi¬cally in utero.
Histologically, CMN is categorized into two major
histologic variants: the classic variant (22 per cent),
which is composed of fascicles of bland fibroblastic
cells with infrequent mitosis and resembles infantile
fibromatosis; and the more common cellular variant
(40-60 per cent), composed of solid sheets of ovoid
cells with frequent mitosis and focal necrosis which
is essentially identical to infan¬tile fibrosarcoma.
A mixed pattern is recognized when features of
both are present in a single tumor. Necrosis and
hemorrhage are naturally more frequent in cellular
variants. Tumour cells are usually positive with
vimentin and focally for smooth muscle actin,
although the diagnosis is based on morphological
criteria alone. The cellular variant shares the same
genetic abnormality as infantile fibrosarcoma: a
t(12;15)(p13;q25) translocation with resultant ETV6NTRK3 fusion. The main factors of importance as
risk factors for local recurrence are cellular subtype
and incomplete local excision at primary surgery.
They relapse within 12 months after the diagnosis, so
during this period a close follow-up is recommended.

Figure: Rhabdoid Tumor of Kidney.

Classic features include large nucleoli, abundant
pink to amphophilic cytoplasm, and intracytoplasmic
globules (arrows)
Congenital Mesoblastic Nephroma
Congenital mesoblastic nephroma (CMN) is a low
grade fibroblastic sarcoma of kidney comprises
two per cent of all paediatric renal tumors. It is
the most common congenital renal neoplasm, with
more than 90 per cent of affected patients are less
than one year of age, about two thirds are diagnosed
in the first three months of life and virtually never
occurring after the age of three years. Most patients
16

Figure: A. Classic form of Congenital Mesoblastic Nephroma.
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Fibromatosis-like growth of well-differentiated
spindle cells with entrapped glomerulus and tubules.
B, Cellular congenital mesoblastic nephroma.
High cell density, mitotically active spindle cell
proliferation, also with entrapped glomeruli.
Renal Cell Carcinomas
Renal cell carcinomas (RCCs) represent around
five per cent of all paediatric renal tumours, hence
they are more common than CMN, CCSK or RTK.
They show distinguishing histological and genetic
features from RCCs seen in adults. These tumours
are defined by several different translocations. A
group of Xp11.2-translocation carcinomas resulting
from fusion of the TFE3 gene is now recognized
as a separate entity. Histologically, they show a
typical nested appearance, but may also be papillary,
composed of cells with granular eosinophilic
cytoplasm or clear cells. Immunohistochemically,
tumour cells show strong nuclear positivity for
TFE3, which is diagnostic. A t(6;11)-translocation
RCC is another translocation-associated paediatric
RCC which has been rarely reported, and is seems
to be less aggressive than Xp11.2-translocation
RCC. Histologically, they feature nests and small
acini of polygonal epithelioid cells with welldefined cell borders, separated by a thin-capillary
vasculature, but also another population of smaller
epithelioid cells clustered around nodules of hyaline
basement membrane material. A number of these
tumours occur as post-chemotherapy tumours,
including after neuroblastoma and nephroblastoma.
Papillary carcinoma can also occur in older
children. Carcinomas of the kidney need to be
considered in children with von Hippel-Lindau
disease and tuberous sclerosis. RCCs with lymph
node metastases generally appear to have a better
prognosis in children.

Large cells with eosinophilic cytoplasm and
psammoma bodies with papillary and compact
architecture.
Renal medullary carcinoma is a rare, highly
aggressive tumour occurring in children and
young adults with sickle cell trait or disease.
Microscopically, it is very infiltrative, and is
composed of large cells with large, vesicular nuclei
and prominent nucleoli (rhabdoid features), usually
accompanied by a marked acute and chronic
inflammatory infiltrate and stromal desmoplasia.
Interestingly, tumour cells may be negative for INI1
marker. Patients usually present with widespread
metastases and show no response to chemo- or
radio-therapy, resulting in a poor survival (mean 4
months).
Conclusion
Renal tumours of childhood are a fascinating group
of tumours where huge progress in classification,
treatment and understanding of molecular biology
has been made. Since these tumours are rare, they
still represent a diagnostic problem and central
pathology review in multicentre trials is essential
for assigning the appropriate treatment. Molecular
biology markers are likely to play an even more
important role in future trials.

Figure: Xp11 Translocation Carcinoma.
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Role of Histopathology in the Diagnosis of
Paediatric Bone and Soft Tissue Small Round
Cell Tumours
Dr Nasir-Ud-Din and Dr Arsalan Ahmed
Histopathology

Introduction
Paediatric bone and soft tissue small round
cell tumours (SRCTs) include Ewing sarcoma,
rhabdomyosarcoma, poorly differentiated
synovial sarcoma, lymphoblastic lymphoma,
desmoplastic small round cell tumour, small cell
osteosarcoma, mesenchymal chondrosarcoma,
melanotic neuroectodermal tumour of infancy, and
neuroblastoma. Accurate diagnosis is crucial as
treatment modalities are different for each tumour. In
this paper we will discuss salient features of each of
these tumours and discuss role of histopathology in
their diagnosis.

strong positivity of CD99 (and negative stains of
other SRCTs) is diagnostic of ES. In difficult cases,
cytogenetic analysis of EWSR1 by FISH or RT-PCR
is needed for diagnosis.

Ewing Sarcoma
Ewing sarcoma (ES) is a high grade sarcoma most
often occur in children and young adolescents, with
a male sex predilection. It commonly involves the
diaphysis of long bones especially femur followed by
sacrum and spinal column. Extraosseous ES is rare
but increasingly recognized due to greater awareness
of this tumor and better techniques of diagnosis. A
typical ES is histologically characterized by sheets of
uniform round cells with scant clear to eosinophilic
cytoplasm, regular nuclear contours, finely dispersed
chromatin and inconspicuous nucleoli. Mitotic
activity is scarce and areas of geographic necrosis are
frequently seen.
A rare histologic variant of ES called atypical ES is
characterized by sheets of large cells with irregular
nuclei and prominent nucleoli, thus mimicking
a large cell lymphoma. Despite their worrisome
features, atypical ESs are similar to typical lesions in
clinical behavior.
A high content of glycogen is seen in cells on
periodic acid-Shiff (PAS) stain. Up to 99 per cent of
ES show diffuse strong membranous expression of
CD99. FLI-1 one is another sensitive marker positive
in approximately 75 per cent cases of ES. In the
appropriate clinical setting, morphology and diffuse
18

Figure 1: Conventional Ewing Sarcoma

showing uniform cells with round, regular nuclei
containing finely dispersed chromatin and scant clear
to slightly eosinophilic cytoplasm. (original
magnification 400x).
Rhabdomyosarcoma
Rhabdomyosarcomas (RMSs) are the most common
malignant soft tissue tumours in children, and
embryonal RMS is most common type, which
commonly arises in the head and neck region with a
minority of cases in the musculature of extremities.
Histologically, embryonal RMS typically displays
alternating areas of hyper and hypocellularity. The
cells vary considerably in differentiation ranging
from primitive and stellate to others having moderate
eosinophilic cytoplasm and still others showing
terminal differentiation with abundant eccentric
eosinophilic cytoplasm and cross-striations. The
hypocellular areas contain myxoid stroma.
Clinical behavior and treatment varies for subtypes
of RMS, so subclassification becomes just as critical
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as diagnosis. Presence of anaplasia in embryonal
RMS should be mentioned in histopathology report
as it is associated with aggressive behavior. The
diagnosis of RMS is made on morphology coupled
with muscle markers desmin, myogenin and Myo
D1.

Figure 3: Poorly differentiated synovial sarcoma.

Note the predominantly round cell cytomorphology
and transition from spindle cells.
Mesenchymal Chondrosarcoma

Figure 2: An embryonal rhabdomyosarcoma

contains rhabdomyoblasts with central or eccentric
nuclei and prominent, brightly eosinophilic
cytoplasm (hematoxylin and eosin, original
magnification x40).
Poorly Differentiated Synovial Sarcoma
Synovial sarcoma (SS) is a relatively common
soft tissue sarcoma that most frequently occurs
in extremities of adolescents and young adults
with a peak incidence between 10 and 35 years.
The three histologic types of SS are monophasic,
biphasic and poorly differentiated. Poorly
differentiated synovial sarcoma (PDSS) tends
to occur more proximally than classical SS, and
is composed of sheets of rounded or ovoid cells
with increased mitotic activity, focal necrosis, and
high proliferation index (Ki67), and resembles
small round cell tumors, such as ES or lymphoma.
PDSS shares a similar immunophenotype to
classic SS such as EMA, Cytokeratin AE1/AE3,
as well as CK7 and CK19. Almost all cases show
nuclear expression of TLE1, a very sensitive but
not specific marker for SS. Variable number of
tumours express CD99, thus causing confusion to
discriminate from ES. In those cases, molecular
analysis of specific chromosomal translocation
t(X;18)(p11,q11) by FISH or RT-PCR helps in
arriving a correct diagnosis as treatment is entirely
different for both tumours.

Mesenchymal chondrosarcoma (MC) is a high
grade sarcoma which mainly affects young adults
and teenagers. Two thirds of cases involve bones
especially ribs and jaw bones and one third of cases
occur in soft tissues adjacent to the craniospinal axis
including paraspinal musculature. Histologically,
MC is characterized by primitive small round cells
arranged in sheets, vague nests or both, often in a
hemangiopericytoma-like vasculature. These cells
usually show an abrupt transition to single or lobules
of well-differentiated hyaline cartilage.

Figure 4: The small blue cell portion of mesenchymal chondrosarcoma
resembling other types of SRCTs, in particular atypical ES. A diagnosis
can be made by finding areas containing the low-grade chondrosarcoma
component.

The differential diagnosis includes other SRCTs such
as atypical ES, and lymphoma, particularly when
matrix component is not evident because of sampling
error. Hematopoietic immunostains will rule out
19
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lymphoma. Potential overlap with ES is exacerbated
by the fact that >90 per cent of MCs show
strong diffuse membranous positivity for CD99.
Alternatively, FLI-1 has been shown to be positive
in 75 per cent of ES and MC is negative. SOX9 is
a useful marker for MC. The stromal component
of small cell osteosarcoma may resemble MC.
Moreover, small cell osteosarcoma also can show
positivity with CD99. Careful attention paid to the
type of matrix production-osteoid in osteosarcoma
and cartilage in MC- is the best way to make the
distinction. Sometimes this requires additional tissue.
Desmoplastic Small Round Cell Tumour
Desmoplastic small round cell tumour (DSRCT)
is an aggressive small round cell neoplasm that
predominantly affects children, adolescents, and
young adults, with a male preponderance. The
tumor characteristically occurs in the abdomen or
pelvis, often with widespread serosal involvement.
DSRCTs almost always consist of small nests of
uniform round cells with hyperchromatic nuclei with
inconspicuous nucleoli and scant cytoplasm set in a
highly vascular, desmoplastic stroma.
DSRCT is of uncertain histogenesis, but it shows
polyphenotypic differentiation, displaying immune
reactivity for epithelial (cytokeratin, EMA and
BerEP4), muscle (desmin), and neural (NSE,
synaptophysin). Desmin staining is usually dot-like,
but muscle specific markers myogenin and MyoD1
are negative. DSRCTs are highly aggressive, with
more than 90% of patients dying from tumour
progression within just a few years.

Small Cell Osteosarcoma
Small cell osteosarcoma is a rare histologic subtype
of osteosarcoma composed of small cells simulating
the appearance of ES or lymphoma. However,
tumour cells produce osteoid or bony matrix, at
least focally. The distinction between ES, especially
atypical ES, and a small cell osteosarcoma can
be difficult because of overlapping histologic and
radiologic features.
Some Ewing sarcomas show fibrinous deposits
among tumor cells, whereas the osteoid in small
cell osteosarcoma is mineralized. Ancillary
studies play an important role in cases in which
osteoid production is questionable. Hematopoietic
immunostains will distinguish lymphoma from small
cell osteosarcoma. Small cell osteosarcoma can be
immunoreactive with CD99, so it is not a useful
stain in ruling out Ewing sarcoma. FLI-1is a better
marker because most Ewing sarcomas are positive
but small cell osteosarcomas are negative. Small cell
osteosarcoma is an extremely uncommon tumor with
a poor prognosis.

Figure 6: The neoplastic cells in small cell osteosarcoma are small,
round, and only occasionally spindle-shaped. The lacelike pattern of
osteoid production differs from reactive bone sometimes seen in other
types of SRCTs of bone.

Neuroblastoma

Figure 5: Desmoplastic Small Round Cell Tumour.

Classic appearance, with sharply demarcated nests
of small round cells within a desmoplastic stroma
containing spindle-shaped myofibroblasts embedded
in a matrix of loose or myxoid extracellular material
and collagen.
20

Neuroblastoma are malignant childhood tumours
derived from primordial neural crest cells.
Neuroblastoma is the third most common childhood
malignant tumor, after hematolymphoid and central
nervous system neoplasms, but the most common
solid tumor of infancy. Patients with metastatic
neuroblastoma to bone are almost always younger
than age five years. A chest and abdominal CT scan
usually detects the primary site in cases where the
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initial diagnosis is made or suggested via a bone
biopsy.
Melanotic Neuroectodermal Tumour of Infancy
(Retinal Anlage Tumour)

VOL. 41, ISSUE 3

white blood cell count, presence of minimal residual
disease after therapy and CNS disease at the time
of diagnosis are associated with adverse outcome.
B-ALL/LBL has a better prognosis in children than
in adults.

Melanotic neuroectodermal tumour of infancy is a
rare tumour usually present in the first year of life
with a moderate predominance in boys. More than 90
per cent of cases arise in the head and neck region,
with an overwhelming predilection for the maxilla.
The tumour has characteristic two principal cellular
components: small basophilic neuroblast-like cells,
often set in a fibrillary matrix, and larger epithelioid,
eosinophlic cells with vesicular nuclei and containing
variable amounts of melanin pigment. The latter cells
are arranged in alveolar or pseudoalveolar structures
set in a dense fibroblastic stroma.
Immunohistochemically, both cell types stain
positively for NSE and synaptophysin; in addition
the larger cells show consistent immunopositivity for
both cytokeratin and HMB-45, in parallel with the
findings in pigmented retinal epithelium.
B-Lymphoblastic Leukemia/Lymphoblastic
Lymphoma (B-ALL/LBL)
B-Acute Lymphoblastic leukemia/lymphomas
occur primarily in children. Bone marrow is nearly
always involved and peripheral blood is also usually
involved. The most frequent extramedullary
sites to be involved by B-LBL include skin,
soft tissue, lymph node and bone. The clinical
presentation is related to pancytopenia secondary to
involvement of bone marrow. Lymphadenopathy and
hepatosplenomegaly are also common. The involved
site is usually composed of sheets of small to
intermediate sized monotonous lymphoblasts which
have indented or convoluted nuclei and inconspicous
to prominent nucleoli. On immunohistochemistry,
the lymphoblasts of B-ALL/LBL show positive
expression for B-cell markers (PAX-5, cC79a, CD19,
CD 24 and cCD22). Of all these markers, PAX-5 is
considered as the most sensitive and specific marker
to demonstrate B-cell lineage. The lymphoblasts
are also positive for CD10 and TdT and negative for
surface immunoglobulin (Ig). Expression of CD20,
CD45 and CD34 is variable. There can be aberrant
expression of myeloid-associated antigens CD13 and
CD33 but Myeloperoxidase (MPO) will be negative.
B-ALL with t(9;22)(q34;q11.2), t(v;11q23) and
hypodiploidy are associated with poor prognosis.
B-ALL with (12;21)(p13;q22) and hyperdiploidy
are associated with favorable prognosis. Ages of
less than one year and more than 10 years, high

Figure 7: B-ALL/LBL A. The neoplastic cells are dyscohesive, are fairly
uniform, have hyperchromatic nuclei, inconspicuous nucleoli and scant
cytoplasm. The B-lymphoblasts show characteristic positive expression
for TdT (B) and PAX 5 (C) immunostains. (original magnification 40x).
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Laboratory Workup of Neonatal Anaemia
Dr Anila Rashid
Hematology

The most common cause of anaemia in young
neonatal anaemia; however, it is often difficult to
infants is “physiologic anaemia”, which occurs
decide which tests to obtain and how to interpret
at approximately six to nine weeks of age.
the results. It is therefore beneficial to proceed
Erythropoiesis decreases dramatically after birth
with investigation in a stepwise manner to avoid
as a result of increased tissue oxygenation and a
unnecessary testing that will delay and confuse
reduced production of erythropoietin. In healthy term
proper diagnosis. The following algorithm can be
infants, hemoglobin (Hb) levels are high (>14 g/dL)
easily followed to help in establishing a diagnosis of
at birth and then rapidly decline, reaching a nadir of
anaemia and its underlying etiology.
approximately 11 g/dL at six to nine weeks of age,
which is called “physiologic anaemia of infancy”.
Diagnostic approach to anaemia in the newborn
Pathologic anaemia in newborns and young infants
is distinguished from physiologic
Anemia
anaemia by any of the following.
(HGB <13.5 g/
dL)

l
l

l

Anaemia (Hb <13.5 g/dL) within
the first month of life
Anaemia with lower Hb level than
is typically seen with physiologic
anaemia (ie, <9 g/dL)
Signs of hemolysis (eg, jaundice,
scleral icterus, or dark urine) or
symptoms of anaemia (eg,
irritability or poor feeding)

Common causes of pathologic anaemia
in newborns include blood loss,
immune hemolytic disease (ie, Rh
or ABO incompatibility), congenital
infection, twin-twin transfusion, and
congenital hemolytic anaemia (eg,
hereditary spherocytosis, glucose-6phosphate dehydrogenase [G6PD]
deficiency). Hyperbilirubinemia in the
newborn period suggests a hemolytic
etiology; microcytosis at birth suggests
chronic intrauterine blood loss or
thalassemia.
Thorough history taking and physical
examination are the primary steps
in identifying the condition and
establishing an etiology, but further
investigations in the form of laboratory
testing are often required to differentiate
the many possible causes.
Laboratory investigations can aid in
determining the underlying cause of
22

Reticulocyte
Count

Increased
reticulocytes

Decreased
reticulocytes

·
·
·
·

Anemia of prematurity
Anemia after Rh incompatibility
Diamond-Blackfan Anemia
Drug induced RBC Suppression

DAT

DAT positive

·
·

Rh or ABO incompatibility
Other blood group incompatibility

DAT Negative

·

Chronic intrauterine blood loss:
· Twin / twin
· Fetomaternal /
· Abruption placentae
Alpha or Beta Thalassemia

·
·
·
·
·
·
·

Hereditary Spherocytosis
Hereditary Elliptocytosis
Hereditary stomatocytosis
Pyknocytosis
DIC
Microangiopathy hemolytic anemias
Hemoglobinopathies

·
MCV

Low MCV

Normal or High
MCV

Peripheral
Smear

Abnormal

Normal

Hemolysis ?

No Hemolysis

Blood Loss

Hemolysis
Present

Congenital RBC enzyme defects
· G6PD deficiency
· PK deficiency
· Hexokinase deficiency
· Others

Infections
·
·
·
·

Bacterial
Viral (CMV, HSV, Rubella, Enterovirus, Adenovirus)
Toxoplasmosis
Fungal

Other
· Galactosemia
· Hypothyroidism

HGB: hemoglobin; RBC: red blood cell; DAT: direct antiglobulin test; MCV: mean
corpuscular volume; DIC: disseminated intravascular coagulation; PK: pyruvate
kinase; G6PD: glucose-6-phosphate dehydrogenase; CMV: cytomegalovirus;
HSV: herpes simplex virus.
Source: Gallagher PG. The neonatal erythrocyte and its disorders. In: Nathan and Oski’s
Hematology and Oncology of Infancy and Childhood, 8th Ed, Orkin SH, Fisher DE, Look AT,
et al (Eds), WB Saunders, Philadelphia 2015. p.52.
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Evaluation of Inborn Errors of Metabolism
(IEM) In a Nutshell
Dr Noreen Sherazi
Chemical Pathology

Inborn Errors of Metabolism (IEM) are single gene
defects, responsible for the abnormalities in the
synthesis or catabolism of proteins, carbohydrates
or fats by way of defective enzymes or transport
proteins, resulting in a block of metabolic pathway.
They are mostly inherited in autosomal recessive
pattern and parent consanguinity increases chance of
inheritance in offspring. IEM was first described by
Garrod at the beginning of the 20th century; several
hundred new disorders have now been defined, as
new robust biochemical and molecular diagnostic
tools became available.
IEM can affect any organ system and usually affect
multiple organ systems. Manifestations vary from
those of acute life threatening disease to sub-acute
progressive degenerative disorders. For evaluating
an IEM it is essential to consider following five
important aspects i.e.:
l

l
l

l

l

Detailed Clinical History: Proper history from
parents has a role in suspecting IEM (Table 1) as
detailed history is necessary for further diagnosis.
Physical examination: To look for dermatitis,
alopecia, facial dysmorphia, cataract etc.
Metabolic screening tests: These include
complete blood count, Urine D/R, plasma glucose,
plasma ammonia, plasma lactic acid, arterial blood
gases and electrolytes
Follow up/Selective screening: The test is
performed on the basis of clinical context which
includes quantitation of amino acids, organic
acids, carbohydrate and other metabolites, Long
chain fatty acids, MPS separation and speciation.
Clinical laboratory AKUH started first local
diagnostic biochemical genetics laboratory in the
country and offering testing facility for screening
and diagnosis of IEMs Table 2.
Definitive diagnostic tests: To confirm the
disorder detected, specific enzyme assays in
leucocytes, plasma/serum or red cells,
immunoassays and DNA/ mutation based analysis
will be tested.

Table 1: Risk Factors in Suspected IEM Disorders
Prenatal Factors Antenatal Factors

Postnatal Factors

Consanguinity

CNS anomalies

Healthy neonate at
birth became sick
after few hours or
days of life

Previous sibling
death

Hydrops fetalis

Refusal to feed

Echogenic kidneys Sepsis, lethargy,
hypotonia
Stippling epiphyses Ketosis, hypoglycemia
Dysmorphic features
Table 2: Initial and Follow Up Testing Facility at Clinical
Laboratory AKUH for IEM Disorders
Metabolic Screening
Panel

Selective or Follow up
Testing Services

 CBC,

 Plasma/ Urine/ CSF
quantification of Amino Acids

 Urine D/R

 Qualitative Urine Organic acids

 Blood Glucose

 Urine Succinylacetone

 Plasma Ammonia

 MSUD Profile

 Plasma Lactic Acid
 Arterial Blood Gases
 Electrolytes

The role of follow-up testing or selective screening
in narrowing the differential diagnosis in suspected
IEM individuals is crucial as per National Academy
of Clinical Biochemistry. (NACB) practice
guidelines Table 3.
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Table 3: Common Disease-Specific Follow-Up Testing Recommendations by NACB
Follow-up
Analyses

Follow-up Markers

Additional Testing

Phenylketonuria

Plasma Amino acids

Phenylalanine

Urine Pterin*, Dihydropteridine
reductase activity*

Tyrosinemia Type 1

Urine organic acids

Succinylacetone

No additional testing

Tyrosinemia Type 2

Plasma amino acids

Tyrosine >1000 μM on
presentation

Maple Syrup Urine Disease

Plasma amino acids

Isoleucine + valine + leucine +
alloisoleucine

No additional testing

Homocytsinuria

Immunoassay

Homocysteine

Folate/Vitamin B12 status
should be investigated

Plasma/Urine amino acids

Methionine, Homocystine

Disorders of cobalamin
metabolism should also be
considered

Urine Organic Acids

Methylmalonic acid

Methylmalonic CoA mutase
activity*

Plasma/Urine amino acids

Argininosuccinate, Citrulline

No additional testing

Methylmalonic acidemia

Urine organic acids

Methylmalonic, 3-OH
propionic, tiglylglycine,
methylcitrate

Complementation analysis,
B12 studies*

Isovaleric Acidemia

Urine organic acids

3-OH isovaleric acid, isovaleryl
glycine

No additional testing

Propionic acidemia

Urine organic acids

3-OH propionic, tiglylglycine,
methylcitrate, propionylglycine

B12 studies*

Multiple Carboxylase
Deficiency

Urine organic
Acids + Plasma
Acylcarnitine*

3-OH propionic, 3 OH isovaleric, tiglylglycine
methylcitrate, 3-MCC
(glycine), lactate

Biotinidase activity,
Isolated carboxylase activities
+ biotin*

Glutaric Aciduria Type 1

Urine Organic acids

Glutaric, 3-OH Glutaric

Glutaric Aciduria Type 2

Urine Organic acids

Glutaric, 2-OH Glutaric, adipic,
suberic, sebacic ethylmalonic,
3-OH isovaleric, isobutyric

Amino Acids Disorders

Argininosuccinic acidemia

Organic Acid Disorders

*Not available at Clinical Laboratories AKUH
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Clinical Utility of Immature Platelet Fraction
– An advanced Parameter in Laboratory
Hematology
Dr Sidra Asad Ali and Dr Muhammad Shariq Shaikh
Haematology

Platelets, first described by a German anatomist as
‘spherules’ nearly a century ago, are multifunctional
anucleated cells that play a vital role in hemostasis.
They are cytoplasmic fragments of megakaryocytes
with dimensions of approximately 2.0–4.0 by 0.5
μm and a mean volume of 7–11 fl. Platelets act as
an initial hemostatic wave through their adhesive
and cohesive properties leading to the formation
of platelet plug with subsequent activation of
coagulation pathways in order to consolidate the
primary hemostatic plug. Average platelet count
ranges between 150 and 410 × 109/L of blood.
However, in patients with thrombocytopenia,
count alone does not provide precise assessment
of bleeding risk and platelet production from
bone marrow. Analogous to red cell reticulocytes,
immature platelets or reticulated platelets are young
platelets that circulate in the peripheral blood and
provide functional status of platelet production by
bone marrow.
Owing to their high ribonucleic acid (RNA) content,
immature platelets can be differentiated from their
mature counterparts. This was first demonstrated
by Kienast and Schmitz in 1990 utilizing flow
cytometry. Since then, several modifications have
been developed utilizing multi-color flow cytometric
analysis and different flouro-chromes providing
simple, rapid and precise assessment of reticulated
platelets. In modern automated hematology analyzers
equipped with this sophisticated method, fluorescent
dyes penetrate the cell membrane through a breach
created by surfactant and label the RNA. It is
reported as percentage of the total platelet count
(%-IPF). The normal reference range for IPF ranges
from 1.6-7.1 per cent in adults and 1.0-6.8 per cent in
pediatric population.
Since IPF provides status of bone marrow
thrombopoiesis, it can be utilized for diagnosis

and management of various disorders.
Raised IPF levels are seen in conditions with
high platelet turn over like disseminated
intravascular coagulation (DIC), thrombotic
thrombocytopenic purpura (TTP) /
hemolytic uremic syndrome (HUS), immune
thrombocytopenic purpura (ITP), blood loss
and others. Whereas, low levels are observed
in individuals with bone marrow suppression
such as aplastic anemia and other bone marrow
failure syndromes, nutritional deficiencies and
drug induced myelosuppression.
Besides its role in aiding the diagnosis of above
disorders, IPF can be utilized to monitor the
diseases process and to assess need of platelet
transfusion. In disorders with high platelet turn
over like ITP, initially high IPF values tend to
decline as the disease responds to treatment.
Similarly, low IPF values in drug induced
myelosuppression and viral hemorrhagic fevers
will return to normal range with improvement in
disease process. Since IPF levels decline around
24-48 hours before improvement in platelet
counts, unnecessary platelet transfusion can be
prevented in such conditions.
In conclusion, IPF is a unique, rapid, noninvasive and in-expensive tool to assess bone
marrow thrombopoietic activity and is available
24/7. All these properties are highly desirable
specifically in paediatric settings where bone
marrow examination may not be always practical.
At AKUH clinical laboratories, state of the art
fully automated hematology analyzers of Sysmex
XE class, incorporate this sophisticated method
of IPF measurement. This test will soon be started
andenable us to provide highly reliable and
important information about thrombopoietic activity
on a single blood sample.
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Multiplex Ligation-Dependent Probe Amplification
(MLPA) to Screen for Mutations Leading
to Duchenne Muscular Dystrophy (DMD)
Dr. Zeeshan A Ahmed, Dr Asghar Nasir and Sheeba Parveen
Molecular Pathology

Duchenne Muscular Dystrophy (DMD) is an
inherited X-linked recessive genetic disorder.
Individuals who inherit it have a defective gene
related to a muscular protein called dystrophin. This
protein keeps muscle cells intact, and its absence
causes rapid muscular deterioration. DMD is a fatal
condition and most sufferers pass away during their
twenties. In the later stages of the disease, sufferers
are completely disabled and require full-time care.
The condition is degenerative. DMD symptoms
may begin to appear between age two and six and
include: difficulty walking or loss of ability to walk,
enlarged calves, learning disabilities, lack of motor
skills development, fatigue and rapidly worsening
weakness in the legs, pelvis, arms, and neck.
Dystrophin, the largest known human gene (2.4 Mb)
is located on the short (p) arm of the X chromosome
at position 21.2. The DMD gene is located from base
pair 31,119,219 to base pair 33,339,609 on the X
chromosome. Mutations in the dystrophin gene alter
the structure or function of dystrophin or prevent
any functional dystrophin from being produced.
This protein is located primarily in muscles used for
movement (skeletal muscles) and in heart (cardiac)
muscle. In skeletal and cardiac muscles, dystrophin
is part of a group of proteins that work to strengthen
muscle fibers and protect them from injury as
muscles contract and relax. Muscle cells without
enough of this protein become damaged and the
damaged fibers weaken and die over time, leading to
the muscle weakness.
Molecular Diagnostic approach to Screen for
Mutations DMD
In suspected DMD patients, an initial investigation
involves studying the levels of creatine kinase (CK).
Normal serum CK levels at presentation excludes
DMD; however an elevated serum CK level obviates
the need for a muscle biopsy with an assay for
dystrophin protein. Molecular testing is useful to
confirm a clinical diagnosis in affected patients.
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For DMD it is recommend to initially screening for
deletions and duplications, followed by a screen for
point mutations if the clinical diagnosis is certain but
a deletion/duplication has not been found, See Figure
1. Since whole exon deletions are the predominant
type of mutation in the DMD gene (65 per cent), an
initial screen which detects the majority of deletions
should be the minimum level of diagnostic test
offered. Currently the most widely used methods
for screening are Multiplex PCR and Multiplex
Ligation-Dependent Probe Amplification (MLPA).
Screening of DMD by MLPA (Multiplex LigationDependent Probe Amplification)
The principle of Multiplex Ligation-dependent Probe
Amplification (MLPA) is based on the amplification
(by use of a single PCR primer pair) of multiple
probes, each of which detecting a specific DNA
sequence of approximately 60 nucleotide in length.
MLPA reagents together with a wide range of MLPA
probe mixes can be used to detect deletions and
duplications in a DNA sample.
Figure 2A shows a typical MLPA reaction. After
denaturation of the sample DNA, a mixture of MLPA
probes is added to the sample. Each MLPA probe
consists of two oligonucleotides that must hybridise
to immediately adjacent target sequences in order
to be ligated into a single probe. Each probe in an
MLPA probemix has a unique amplicon length,
typically ranging between 130-500 nucleotides.
During the subsequent PCR reaction, all ligated
probes are amplified simultaneously using the same
PCR primer pair. One PCR primer is fluorescently
labeled, enabling the amplification products to be
visualized during fragment separation. This is done
on a capillary electrophoresis instrument, yielding
a specific electropherogram. The relative height
of each individual probe peak, as compared to the
relative probe peak height in various reference
DNA samples, reflects the relative copy number of
the corresponding target sequence in the sample.
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A deletion of one or more target sequence thus
becomes apparent as a relative decrease in peak
height while an increase in relative peak height
reflects amplification. Figure 2B shows MLPA
results with probe P034 in normal control sample
(top panel) compared with a case of deletion (middle
panel) and a case of duplication (bottom panel).
DMD can be caused by deletions, duplications
or point mutations in the DMD gene that
encodes the protein dystrophin, however to what
extent DMD manifests depends on whether the
translational reading frame is lost or maintained.
Partial gene deletions or duplications in the DMD
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gene account for as much as ~65% of cases of
these dystrophies. This extremely high percentage
may be due to the nature of the protein and the
gene’s extreme length (> 2.2 Mb). The MLPA
based DMD probemix contains probes for each of
the exons of the DMD gene (79 exons) on Xp21.2
chromosome. Performing MLPA reactions is thus
sufficient to investigate the copy number of all
exons.
In conclusion, MLPA offers a more extensive
screening than many other methods used in DMD
analysis as it makes possible to find deletions/
duplications that were previously overlooked.

Figure 1: Molecular Diagnostic approach to Screen for DMD Gene Mutation
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Figure 2: MLPA reaction (A) results showing deletion and duplication (B).
2A. Reproduced from MRC-Holland - Products - Details - P034 DMD mix 1
2B. Reproduced from Sakthivel Murugan S.M., et al 2013

An Update on Blood Lead Levels in Children
Dr Hafsa Majid
Chemical Pathology

Childhood lead poisoning is one of the most
common and entirely preventable diseases of
toxic environmental origin. It remains a problem
of enormous importance for child health and
development worldwide and lead poisoning
accounts for about 0.6 per cent of the global burden
of disease. The condition is worse especially in
developing countries, as due to limited available
resources there focus remains on infectious
diseases. Lead plays no essential role in the human
body and is ubiquitous in the environment leading
to clinical and subclinical toxicity primarily through
ingestion and inhalation.
28

The American Academy of Pediatrics and Centers for
Disease Control and Prevention (CDC) recommend
that blood lead screening be done of all children at
the ages of approximately one and two years. The
levels are evaluated according to cutoffs defined
by CDC, which are now updated after every four
years based on recent evidence of lead related
health hazards and United States NHANES surveys
reporting lead exposure in children. Recently
recommended CDC action lead level of children for
the period of 2012-2016 are <5ug/dl. But mounting
evidence now is showing that blood lead levels
(BLLs) that were considered previously to be safe
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can compromise health and injure multiple organs,
even in the absence of overt symptoms. Recent
research indicates that lead is associated with
neurobehavioural damage at blood levels of 5 µg/dl
and even lower. So there appears to be no threshold
level below which lead causes no injury to the
developing human brain.
The gravest consequence of low level or subclinical
lead toxicity in childhood is damage to the
developing brain and nervous system and as the
human brain has little capacity for repair, so the
hazardous effects are untreatable and irreversible.
The immune, reproductive and cardiovascular
systems are also adversely affected by relatively
low levels of exposure to lead. The Joint FAO/WHO
Expert Committee on Food Additives reevaluated
lead in June, 2010 and withdrew the provisional
tolerable weekly intake guideline value on the
grounds that it was inadequate to protect against IQ
loss. Researchers are proposing even lower action
lead levels then recommended by CDC and in few
countries government agencies have already lowered
their BLL cutoffs as well as recommendations
regarding selective screening to mandatory screening
for all children, for example Germany; action BLL
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for children are now lowered to <3.5ug/dl.
Avoidance of lead exposure remains the primary
preventive strategy for reducing adverse health
effects of lead poisoning. So approaches to reduce
lead exposure should by adopted, on local as well as
public level. Exposure sources should be identified
and eliminated or controlled to reduce this trace
metal’s environmental toxicity. Along with it action
BLL should be redefined for our population and
awareness should be raised regarding this issue at
all levels; among public health officials, healthcare
providers as well as general public.
Blood Lead Levels Testing at AKUH Clinical
Laboratory
Blood lead levels are analyzed to detect and confirm
exposure to lead. It may also be ordered to monitor
the effectiveness of treatment and to confirm that
lead levels are decreasing over time. At AKUH
Clinical Laboratory lead is analysed by Graphite
Furnace Atomic Absorption Spectrometry. For
analysis 4 cc whole blood in Lithium Heparin tube
is needed. Please note the sample should not be
centrifuged or plasma must not be separated as whole
blood is required.

Quiz Answers:
1. Hypophosphatemic rickets or X linked
Hypophosphatemic (XLH) rickets, usually
presents with typical signs of rickets in young
children.
2. To confirm Hypophosphatemic rickets, as it is
accompanied by hypophosphatemia and low
TmP/GFR hence TmP/GFR calculation will
confirm his suspicion.
3. The TmP/GFR estimate the ratio of phosphorus
tubule maximum (TmP) to glomerular filtration
rate (GFR), to evaluate renal phosphate transport.
Ratio is calculated by following formula:
Tmp/GFR= SPO4 – [(UPO4×SCr)/ UCr]
4. The XLH rickets is caused by various mutations
in the PHEX gene (Xp22.1) and is transmitted as
an X-linked dominant trait with complete
penetrance, but variable expressivity. PHEX
encodes an endopeptidase expressed

predominantly in bone and teeth that regulates
fibroblast growth factor 23 (FGF-23) synthesis.
PHEX mutations lead to increased circulating
levels of FGF-23, a phosphate-regulating
hormone (phosphatonin), that leads to reduced
renal phosphate reabsorption and consequently
abnormal bone mineralization. Eventually there
is decreased proximal renal tubular resorption
of phosphate, resulting in renal phosphate
wasting and hypophosphatemia due to
these circulating phosphatonins. The principle
phosphatonin in hereditary hypophosphatemic
rickets is FGF-23.
5. 1,25-dihydroxyvitamin D should be tested.
Patients with XLH have normal or low
serum levels of 1,25-dihydroxyvitamin D3
(also known as calcitriol, the active form of
vitamin D), despite having hypophosphatemia,
which is a known stimulus of 25-hydroxyvitamin
D-1-alpha-hydroxylase activity.
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Meeting Report: “Les Confluences” The Society
for the Study of Inborn errors of Metabolism
(SSIEM) Annual Symposium 2015 in Lyon, France
Dr Noreen Sherazi
Chemical Pathologist

SSIEM is aimed to foster the study of inherited
metabolic disorders and related topics. It promotes
exchange of ideas between professional workers in
different disciplines who are interested in inherited
metabolic disease. The origin of SSIEM may be
traced to an informal meeting held in England at the
Manchester Royal Infirmary in 1962 when an
enthusiastic group of biochemists and pediatricians
met to discuss phenylketonuria.

The day one commenced with an attractive scientific
program including informative ERNDIM meeting
regarding critical errors in proficiency testing
followed by Industry Sponsored Symposia on PKU,
lunch and poster walk. There was opening ceremony
and plenary session on “confluence of research and
inborn errors” followed by a refreshing welcome
reception towards the end of a hectic day.
The annual symposium of SSIEM 2015 was held in
Lyon from 1st till 4th September at Lyon Convention
Centre which was located at the Cité Internationale
de Lyon between the Parc de la Tête d’Or and the
Rhône River. The theme of the symposium was taken
from the word “Les Confluences”: where Rhône
and Saone rivers join in French. In SSIEM, all health
professionals work together and when basic research
helps clinicians. This symposium was attended by
two Chemical Pathologist Dr. Aysha Habib Khan
and Dr. Noreen Sherazi and Metabolic Physician Dr.
Bushra Afroze from Aga Khan University, Karachi.
Abstract regarding frequency of selective screening
of organic acidurias and amino acidopathies was
selected for poster presentation and two other
abstracts were published in abstract book related to
quality control and proficiency testing of biochemical
genetics laboratory, AKU.
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Day two started with the parallel session on
Organic acidurias/Urea cycle disorders, Amino
acids disorders and Mitochondrial disorders where
researchers from France, Switzerland and Italy
presented their work on various topics including
MMA, propionic acidurias, GA type one, OTC
deficiency and mutations causing 3-methylglutaconic
acidurias etc. A very informative plenary session
on “Antenatal manifestations of IEMs discussed
fetopathological investigations, diagnostic workup
and imaging findings of IEMs in antenatal period
after the lunch.
Day three had various plenary sessions on riboflavin
and fatty acid oxidation, neurometabolic disorders,
vitamins and cofactors and disorders of lysosomal
storage. One hour industry sponsored session on
“Metabolic decompensation in PA and MMA” was
very practical and interactive session. Last day was
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also concluded with plenary sessions, hot topics
and late breaking news, Garrod award lecture on
transcobalamin deficiency and closing remarks with
SSIEM Rome 2016 presentation and awards.
Over all the sessions were clinical oriented and
research based but as a pathologist these sessions
were beneficial in gaining clinical perspective in the
area of IEM as it will enhance the understanding
of inherited disorders and quality of diagnostic
reporting along with the future developments in the
field of IEM.
Lyon is internationally known for its gastronomy,
which was shared with us during the networking
afternoon on day three where we had the opportunity
to discover different aspects of the Capitale des
Gaules, a UNESCO World Heritage site since 1998.
It was great honor to present the biochemical
genetics laboratory two years data on selective
screening of organic acidurias and amino
acidopathies from AKUH at the international
symposium of SSIEM 2015. This was first local data

of IEM diagnosed with locally available expertise in
Pakistan. Not only abstract was selected for poster
presentation but they have also awarded travel
scholarship to Dr. Noreen Sherazi in order to attend
the annual symposium 2015. This project was the
collaborated efforts of Faculty of Section of Clinical
Chemistry, Department of Pathology and Laboratory
Medicine, Technical staff of Biochemical genetics
unit and Metabolic Physician, Dr. Bushra Afroze
from Pediatrics Department AKUH.
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